Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An acute leukemia characterized by the proliferation of both neutrophil and monocyte precursors. (WHO, 2001)
Biomarker and diagnostic research for acute myelomonocytic leukemia M4 has been reported in the published literature.
Estimated prevalence: 1-9 in 1,000,000 (Rare).
1 clinical trial registered. Interventions under study include other interventions and gene therapy. Research is primarily sponsored by academic and government institutions.
123 publications have been identified in PubMed for acute myelomonocytic leukemia M4. Research spans Basic Science / Preclinical (29%), Review / Meta-Analysis (16%), and Clinical Trial Publication (13%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 36 | 29% |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 5:38 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about acute myelomonocytic leukemia M4
Research summaries |
20 |
16% |
Clinical study results | 16 | 13% |
Disease patterns and progression | 16 | 13% |
Patient case studies | 15 | 12% |
Testing and diagnosis research | 14 | 11% |
Other research | 3 | 2% |
New treatment approaches | 3 | 2% |
Vardanyan S (2026). [PMID: 41943513](https://pubmed.ncbi.nlm.nih.gov/41943513/). *Expert Rev Hematol*. [Other]
Liao P (2026). [PMID: 42145737](https://pubmed.ncbi.nlm.nih.gov/42145737/). *Front Med (Lausanne)*. [Basic Science / Preclinical]
Hsia B (2026). [PMID: 42127746](https://pubmed.ncbi.nlm.nih.gov/42127746/). *Hematol Transfus Cell Ther*. [Diagnostic / Biomarker]
Parsi M (2026). [PMID: 31082180](https://pubmed.ncbi.nlm.nih.gov/31082180/). *Unknown Journal*. [Basic Science / Preclinical]
Huber S (2026). [PMID: 41860384](https://pubmed.ncbi.nlm.nih.gov/41860384/). *Blood Adv*. [Basic Science / Preclinical]
Chen Y (2026). [PMID: 41346291](https://pubmed.ncbi.nlm.nih.gov/41346291/). *Blood Adv*. [Basic Science / Preclinical]
Komori T (2026). [PMID: 41631723](https://pubmed.ncbi.nlm.nih.gov/41631723/). *Br J Haematol*. [Clinical Trial Publication]
Mohamed SF (2026). [PMID: 41898318](https://pubmed.ncbi.nlm.nih.gov/41898318/). *Biomedicines*. [Review / Meta-Analysis]
Tsushima T (2026). [PMID: 41872671](https://pubmed.ncbi.nlm.nih.gov/41872671/). *Cancer Med*. [Epidemiology / Natural History]
Konopleva M (2026). [PMID: 41492241](https://pubmed.ncbi.nlm.nih.gov/41492241/). *Am J Hematol*. [Other]